Journal of hospital medicine · 2021
Gender Differences in the Presentation and Outcomes of Hospitalized Patients With COVID-19.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biolè Carloalberto, Bianco Matteo, Núñez-Gil Iván J, Cerrato Enrico, Spirito Amanda, Roubin Sergio Raposeiras, Viana-Llamas María C, Gonzalez Adelina, Castro-Mejía Alex F, Eid Charbel Maroun, Fernández-Pérez Cristina, Uribarri Aitor, Alfonso-Rodriguez Emilio, Ugo Fabrizio, Guerra Federico, Feltes Gisela, Akin Ibrahim, Fernández-Rozas Inmaculada, Blasco-Angulo Natividad, Huang Jia, Aguado Marcos Garcia, Pepe Martino, Romero Rodolfo, Becerra-Muñoz Víctor Manuel, Estrada Vicente, Macaya Carlos
Аннотация
Gender-related differences in COVID-19 clinical presentation, disease progression, and mortality have not been adequately explored. We analyzed the clinical profile, presentation, treatments, and outcomes of patients according to gender in the HOPE-COVID-19 International Registry. Among 2,798 enrolled patients, 1,111 were women (39.7%). Male patients had a higher prevalence of cardiovascular risk factors and more comorbidities at baseline. After propensity score matching, 876 men and 876 women were selected. Male patients more often reported fever, whereas female patients more often reported vomiting, diarrhea, and hyposmia/anosmia. Laboratory tests in men presented alterations consistent with a more severe COVID-19 infection (eg, significantly higher C-reactive protein, troponin, transaminases, lymphocytopenia, thrombocytopenia, and ferritin). Systemic inflammatory response syndrome, bilateral pneumonia, respiratory insufficiency, and renal failure were significantly more frequent in men. Men more often required pronation, corticosteroids, and tocilizumab administration. A significantly higher 30-day mortality was observed in men vs women (23.4% vs 19.2%; P = .039). Trial Numbers: NCT04334291/EUPAS34399.